Healthcare Industry News: spectroscopy
News Release - December 6, 2011
Spectros Corporation Signs Distribution Agreements in Middle EastPORTOLA VALLEY, Calif. , Dec. 6, 2011 -- (Healthcare Sales & Marketing Network) -- Spectros Corporation announced today an expansion of its distribution channels in the Middle East with the signing of distributors based in the UAE, with expansion to other areas of the Middle East under discussion. These groups will join other distributors already selling Spectros products outside of the U.S.
"We are excited by this continued expansion," noted Director of Sales Elizabeth van Thillo-Rohlff . "More and more physicians are recognizing the opportunity offered by the superior Spectros T-Stat® tissue oximeter, as was confirmed in recent independent studies."
Spectros T-Stat Oximeter is currently the only broadband tissue oximeter on the market in the U.S. and Europe . T-Stat competes in the marketplace with INVOS® oximeters marketed by Covidien, and FORE-SIGHT® oximeters marketed by CAS Medical. In reconstructive surgery, T-Stat competes with oximeters marketed by ViOptix.
An expanded array of probes, including broadband infrared Continuum® monitor, Ceres™ cerebral probes, and multi-site T-Stat monitors are currently in testing, pending FDA approval and release anticipated over the next year.
Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's champion product, the T-Stat Tissue Oximeter, is the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue. T-Stat is the only commercially-available tissue oximeter that utilizes state-of-the-art broadband visible light spectroscopy (VLS). The non-invasive T-Stat system is used clinically to provide a continuous and real-time absolute value, utilizing 260 wavelengths, over the competing oximeter product lines that only use 2-4.
Spectros also develops molecular diagnostic tools for breast and prostate cancer, currently in phase I/II clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.
(Note: Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns. Certain Spectros applications described above have not been reviewed and approved by the FDA, and are therefore labeled "for investigational use only." T-Stat, Continuum, and CereS are trademarks of the Spectros Corporation. INVOS is a trademark of Somanetics and Covidien. FORE-SIGHT is a trademark of CAS Medical).
For further information, visit www.spectros.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.